A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients.
about
The blind men and the AML elephant: can we feel the progress?Acute Myeloid Leukemia: A Concise ReviewAn update of current treatments for adult acute myeloid leukemiaFuture prospects of therapeutic clinical trials in acute myeloid leukemia.Strategies for reducing the treatment-related physical burden of childhood acute myeloid leukaemia - a review.Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia.Molecular therapy for acute myeloid leukaemia.The outcome and prognostic factors of 248 elderly patients with acute myeloid leukemia treated with standard-dose or low-intensity induction therapy.Acute Myeloid Leukemia: Advancements in Diagnosis and Treatment.Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.Acute myeloid leukemia--major progress over four decades and glimpses into the future.Acute myeloid leukemia in the elderly: therapeutic options and choice.Gemtuzumab ozogamicin in acute myeloid leukemia.The safety of treatment options for elderly people with acute myeloid leukemia.Frontline treatment of acute myeloid leukemia in adults.High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients.Acute Myeloid Leukemia in the Elderly Patient: New StrategiesAcute myeloid leukemia: 2016 Update on risk-stratification and management.Clinical Relevance of RUNX1 and CBFB Alterations in Acute Myeloid Leukemia and Other Hematological Disorders.What Is the Optimal Induction Therapy for Younger Fit Patients With AML?What Is the Best Daunorubicin Dose and Schedule for Acute Myeloid Leukemia Induction?Cladribine, cytarabine and idarubicin (CLA-Ida) salvage chemotherapy in relapsed acute myeloid leukemia (AML).The preclinical discovery of vosaroxin for the treatment of acute myeloid leukemia.Addition of cladribine to the standard induction treatment improves outcomes in a subset of elderly acute myeloid leukemia patients. Results of a randomized Polish Adult Leukemia Group (PALG) phase II trial.Treatment of older patients with acute myeloid leukemia (AML): revised Canadian consensus guidelines.Comparison of the effects of early intensified induction chemotherapy and standard 3+7 chemotherapy in adult patients with acute myeloid leukemia.The FLAM regimen: revisiting time sequential induction therapy for patients with poor-risk acute myeloid leukemia.Emerging therapeutic modalities for acute myeloid leukemia (AML) in older adults.Acute myeloid leukaemia.The rocky road to personalized medicine in acute myeloid leukaemia.Durable graft-versus-leukaemia effects without donor lymphocyte infusions - results of a phase II study of sequential T-replete allogeneic transplantation for high-risk acute myeloid leukaemia and myelodysplasia.HLA-Mismatched Microtransplant in Older Patients Newly Diagnosed With Acute Myeloid Leukemia: Results From the Microtransplantation Interest Group.Impact of body-surface area on patients' outcome in younger adults with acute myeloid leukemia.Distinct genetic alteration profiles of acute myeloid leukemia between Caucasian and Eastern Asian population.Improved outcome for AML patients over the years 2000-2014.Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia.Timed sequential therapy for acute myelogenous leukemia: Results of a retrospective study of 301 patients and review of the literature.Cytarabine and daunorubicin for the treatment of acute myeloid leukemia.Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure.Acute myelogenous leukemia in adolescents and young adults.
P2860
Q26749614-40796518-EB6A-41B8-9D37-0F5DC2E5505CQ26766719-5AB067B7-80F0-4A36-9CBB-B839B24904A3Q26776396-1D490F6A-F6DF-44F2-92E1-D245DF356306Q30244168-7330D553-0FE6-4E70-8376-9481715FA51EQ30244244-028D47E4-160B-43CA-BC26-F04A8E15BB16Q33643108-E750113D-5867-4C2F-8E1D-4FEC787453BCQ33925672-4E4681F4-1E53-493C-BC56-2F5AEE164CC7Q37605585-2254750B-2DED-4C06-BE51-1EE4E0D4C1F0Q37615574-3A23F041-43F2-45CB-987B-0D1CD1DDF111Q37624593-17B9F59D-D849-441B-8CA9-63C5B3D95728Q38644941-D3BE74CC-FACB-48B7-808B-A8A1C1E4424DQ38675781-736D883B-47F4-4E21-8B96-C0D8E6CFF8F9Q38728718-A3B11873-BF4E-4B9F-84CF-D94083BC98FCQ38760822-A550D6EC-1FC8-405A-AF78-B19FCAE22874Q38767583-A121E6F6-7C6D-47DA-8081-0D5343DA1382Q38809840-77191DFA-18EE-49CA-9DD9-39333534B173Q38835119-8A07D488-678B-4C33-B74D-988488DE439FQ38897289-4E14DBCA-8D32-4F7E-8AF9-D9F6B344A905Q38904250-21326842-3E4A-4500-A5B2-DC23E7D3D242Q38913554-3B149869-BAD9-4D97-B32F-4389865CDE30Q39116969-792E1050-77AD-42EF-BC3E-DB77F8CC4182Q39296422-19BDB58D-06B1-44CF-B6F7-25F949AA1C0FQ39306416-06D65798-8214-4962-9B62-58325BB83B3FQ40373192-B35AFE89-B352-4F4B-AE88-825C7B112A45Q41265804-4F32C54F-3CD9-4E61-B215-8E359F7D30DAQ42377773-CE9FEF8B-D0F8-471D-A89A-B9AC0D628661Q42943359-1571B8F8-ECEF-47FB-87A2-433C90AAC377Q46168137-0AC7F1DE-983B-4FBB-B8B9-7CA9AA07F6D8Q47432401-8D727AAC-9B6A-4206-B26B-6F2CCABFE5A4Q47561008-DD956DD9-45B7-4B4C-89A7-CD170004C573Q47598339-371FD26B-4941-41C7-96C7-E53CE58D306CQ47639413-AD9E1F12-F1DA-42E0-A9A1-AA3FF0CFA527Q48312577-B3AAEBEB-6826-4BC4-8FF2-1F1ED96A4038Q49481329-50E39439-8C12-4ACF-98FC-2AC2A301E3BBQ49566124-D31498EF-7C11-4187-A3EA-C4F15A7FB5EDQ49614743-EF92CE24-7588-4198-9356-E200748B9502Q49840237-7009BDB1-BDB3-472F-9402-FE6C758975C7Q50090381-6BA6A20C-7B71-46BD-8CE1-7D836BD0E805Q50923400-07DADD4A-00E8-4A09-8B22-9B5593758219Q52318200-04BD7B10-4A3A-4F89-8DC4-7DD46895F643
P2860
A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
A randomized comparison of dau ...... AML17 trial in 1206 patients.
@ast
A randomized comparison of dau ...... AML17 trial in 1206 patients.
@en
type
label
A randomized comparison of dau ...... AML17 trial in 1206 patients.
@ast
A randomized comparison of dau ...... AML17 trial in 1206 patients.
@en
prefLabel
A randomized comparison of dau ...... AML17 trial in 1206 patients.
@ast
A randomized comparison of dau ...... AML17 trial in 1206 patients.
@en
P2093
P2860
P1433
P1476
A randomized comparison of dau ...... AML17 trial in 1206 patients.
@en
P2093
Alan K Burnett
Don Milligan
Ian F Thomas
Jamie Cavenagh
Jonathan Kell
Lars Kjeldsen
Lone Friis
Mary-Frances McMullin
Mike Dennis
Nigel H Russell
P2860
P304
P356
10.1182/BLOOD-2015-01-623447
P407
P577
2015-04-01T00:00:00Z